


A Next Generation Stem Cell Company

Dr Ross Macdonald, CEO, Cynata Therapeutics Limited

February, 2015



Important information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).




Cynata Therapeutics Ltd Key Facts

| | |
|-------------------------|--|
| ASX: | CYP |
| Commenced Operations: | November, 2013 |
| Market Cap (20 Feb 15): | A\$58m |
| Shares on Issue: | 66.0m |
| Cash (30 Dec 14): | A\$6.2m (~24 months runway) |
| Number of shareholders: | ~1150 |
| Business focus: | Regenerative medicine: mesenchymal stem cells |

| | | |
|-----------------------|------------------------------|------------|
| Major holders: | Celtic Capital Pte Ltd | 4.01% |
| | Mr Ian Dixon | 3.61% |
| | Prof Igor Slukvin | 3.61% |
| | John W King Nominees Pty Ltd | 2.84% |
| | <i>Top 25 shareholders</i> | <i>50%</i> |

Regenerative Medicine



Why are Mesenchymal Stem Cells Important?

Mesenchymal Stem Cell (MSC) therapies are here and now:

| | |
|----------------------------------|--------------------------------------|
| Spinal cord injury | Neurodegenerative diseases (eg MS) |
| Eye diseases (eg AMD) | Chronic wounds |
| Stroke | Myocardial infarction (heart attack) |
| Graft-versus-host disease (GvHD) | Bone fracture; cartilage repair |
| Osteoarthritis | ++++ |

- ~280* open clinical studies using MSCs in areas of major unmet medical need, eg stroke:
 - US market for stroke therapies estimated to approach \$1b by 2017¹;
 - cost of strokes in US: \$39b p.a. with 795,000 patients p.a.²
- Particular relevance to chronic diseases of ageing
- Profound legislative changes to expedite stem cell therapies (eg Japan)

*www.clinicaltrials.gov

1. GlobalData: Acute Ischaemic Stroke Market Value 2013
2. US Centre for Disease Control and Prevention

Cynata's Stem Cell Manufacturing Breakthrough

- Cynata recently announced the validation of its Cymerus™ MSC manufacturing technology for therapeutic scale-up: **so what?**
- Currently, commercial-scale manufacture of MSC products is a major practical & regulatory challenge
 - Donor reliance: different donor = different stem cell = different product
 - Invasive procedure: eg bone marrow extraction
 - Limited expansion potential: supply constraint
 - Impure MSC populations: immunogenicity

= inconsistent clinical results, low margins and regulatory uncertainty

Cynata's Cymerus™ technology facilitates commercial-scale manufacture of a consistent, reproducible product:

... “better, cheaper, faster”

Cymerus™: World-first MSC Manufacturing Technology

- Completion of tech transfer at Waisman Biomanufacturing:




*From the lab
bench....to:*

GMP process development, scale-up, validation, documentation



- Confirmation that the Cymerus™ process can be scaled-up, enabling reproducible manufacture of a consistent MSC product in a GMP environment
- Manufacture of MSCs for clinical program now underway

Cynata's Stem Cell Manufacture (Cymerus™)



- No more cottage industry: commercial scale manufacture
- Unlimited MSC stem cell doses from single, one-time donor
- Reproducible, clinical grade premium quality MSCs
- Consistent quality = consistent efficacy = pharmaceutical product

Manufacturing issues attracting global attention

Cytotherapy, 2013; 15: 2–8

International Society for Cellular Therapy
ISCT

REVIEWS

The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

JACQUES GALIPEAU

Departments of Hematology & Medical Oncology and Pediatrics, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

“the most egregious divergence between [commercial and academic MSC products] is the scale of product expansion. The industrialization of MSC manufacturing has favoured the production of large lots of 10,000 doses from each volunteer donor”

“the hypothesis that cells approaching replicative exhaustion are functionally distinct from manufactured MSCs devoid of such exhaustion ... may provide a mechanistically based rationale justifying use of modestly expanded MSCs for GvHD”

CLINICAL RESEARCH

ASBMT
American Society for Blood
and Marrow Transplantation

Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy

Lena von Bahr, Berit Sundberg, Lena Lönnies, Birgitta Sander, Holger Karbach, Hans Hägglund, Per Ljungman, Britt Gustafsson, Helen Karlsson, Katarina Le Blanc,* Olle Ringdén*

“[lower] number of MSC expansion passages could be correlated to both better response and better survival”



Democratizing Cell Technologies

A RoosterBio Blog

Strategies, tools & technologies for simplifying the incorporation of living cells into tomorrow's products.

RoosterBio

[Home](#) [About Us](#) [RoosterBio Website](#) [Simple, Cost Effective hMSCs](#)

July 7, 2014

Best Practices in MSC Culture: Tracking and Reporting Cellular Age Using Population Doubling Level (PDL) and not Passage Number

Follow by Email

Email address...


“it is well documented that cell phenotype and function can be compromised the older a cell is”

“the regulators are going to ask that you define experimentally, backed up with data, the maximum PDL that will be used for clinical use. Lack of data in this area will likely not keep one out of a Phase 1 trial, but the further the product progresses in development and the clinical pipeline, this type of information is typically mandatory”

Cynata's Cymerus™ : Outstanding Pedigree



THE UNIVERSITY
of
WISCONSIN
MADISON



- Inventors include Dr James Thomson
 - In 1998 derived the first human embryonic stem cell line
 - 2007 derived human induced pluripotent stem cells
- Prof Igor Slukvin, co-founder and author of >70 publications in the stem cell field
- In-licensed intellectual property includes several issued US patents as well as a broad estate of issued and pending patents



Cymerus™ Critical Limb Ischaemia Study

Control



Cymerus™ cells



Stem Cell Company Market Valuations

| Company | Mkt cap | Development stage | Partners | Cash ⁺ |
|-----------------|---------|------------------------------|-------------------|-------------------|
| Mesoblast (Aus) | \$1.3b | 5 x P3/P3 ready 1 x filed | Teva JCR Pharm | \$150m |
| Asterias (USA) | \$154m | 1 x Ph1/2 ready | nil | \$6.4m* |
| Cynata (Aus) | \$27m | Manufacturing validated | pending | \$6.2m |

- Cynata capitalised well below comparable stem cell companies
- Cynata risk profile substantially lower
- Cynata only company able to manufacture a consistent, reproducible MSC product, independent of further stem cell donors

As at 18 Feb 2015

⁺most recent filings

*closed US\$5.5m raise Feb 15

\$ = AUD as converted

Cynata Value Catalysts

- Recent achievements:
 - Validated manufacturing scale up and process development (Waisman)
 - In-licensed clinical grade iPSC line (CDI)
 - Further PoC study underway (following successful CLI study)
 - Regulatory review and roadmap
 - Partnerships (announced UWA)
 - Research coverage (Baillieu Host; BBY; both “buy” ratings)
 - Clinical trial logistics CRO
- Next steps:
 - Continued discussions with potential partners
 - Develop plans and schedule for clinical trial
 - Data from pre-clinical program and PoC study in GvHD model
 - Ongoing formal interaction with regulatory agencies (eg FDA)
 - Continued success of MSC-based therapeutics



Path to Revenue

- Two routes to monetise the Cymerus™ technology
 - Make our own stem cell medicines (GvHD and others progressing): confirm efficacy; *cheaper, better, faster*
 - Capital efficient license-driven strategy: partner with big pharma/big biotech (in discussions); revenue through license fees, R&D payments and royalties; potential for M&A
- ***Cymerus™ = unlimited high quality stem cells for medicine***

Cynata Board and Management

Executive Chairman: **Dr Stewart Washer**

Managing Director & CEO: **Dr Ross Macdonald**

VP Product Development: **Dr Kilian Kelly**

Non-executive Director: **Dr John Chiplin**

Non-executive Director
and Company Secretary: **Mr Peter Webse**

- A tight team with extensive industry, cell therapy and public company experience plus a track record of commercialising therapeutic products

Why Invest Now in Cynata Therapeutics?

- Vibrant and expanding field of stem cell medicine
- Global demand for stem cell therapeutics (ageing population)
- Innovative technology from established & prestigious centre
- Cymerus™ overcomes critical shortcoming in commercial stem cell production
- Capital efficient, licensing-driven business strategy
- Experienced management team
- Value-accretive news flow expected in near term
- Potential revenues from therapeutic products and world-first platform technology

Thank you for your attention



Contact details: e: ross.macdonald@cynata.com
p: +61 (0) 412 119343